China indapamide market is estimated to grow at a CAGR of around 4.1% during the forecast period. The market is mainly driven due to growing various heart-related diseases and other diseases in the country. Lack of physical activity, obese population, alcohol consumption, unhealthy diet, and smoking are some major factors leading to the rising number of incidences of these conditions. The rising aging population may further increase the risk of hypertension in China. With the age, arteries get stiffer and thereby blood pressure goes up. Apart from the aging population, the condition has been shown to increase among adults in the country. As per the findings by the researchers at Yale and the Chinese National Center for Cardiovascular Disease published in October 2017, over one-third of adults in China are suffering from high blood pressure. Hypertension raised the risk of severe health problems, such as heart attack and stroke. The use of indapamide supports to reduce the blood pressure and the risk of having other severe condition among patients.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/china-indapamide-market
China indapamide market is segmented on the basis of product and application. Based on the product, the market is bifurcated into 1.25 mg indapamide and 2.5 mg indapamide. Among these, the market for 1.25 mg indapamide held a significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have a significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.
The companies which are contributing to the growth of the China indapamide market include Glenmark Pharmaceuticals Ltd, Shandong Yinfeida Pharmaceutical Co., Ltd., Suzhou Lixin Pharmaceutical Co., Ltd., Merck KGaA, Sanofi S.A., and others. The market players are considerably contributing to the market growth by adopting various strategies including new product launch, merger, and acquisition, collaborations to stay competitive in the market.
China Indapamide Market- Segmentation
By Product
- 25 MG
- 5 MG
By Application
- High Blood Pressure
- Heart Failure
- Others
A full report of China Indapamide Market is available at: https://www.omrglobal.com/industry-reports/china-indapamide-market
Company Profiles
- ANI Pharmaceuticals, Inc.
- Glenmark Pharmaceuticals Ltd.
- Merck KGaA
- Sandoz International GmbH
- Sanofi S.A.
- Shandong Yinfeida Pharmaceutical Co., Ltd.
- Supra Chemicals
- Suzhou Lixin Pharmaceutical Co., Ltd.
- Taj Pharmaceuticals Ltd.
- Torrent Pharmaceuticals Ltd.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
